These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 8149546

  • 21. Nonpeptide glycoprotein IIb/IIIa inhibitors. 5. Antithrombotic effects of MK-0383.
    Lynch JJ, Cook JJ, Sitko GR, Holahan MA, Ramjit DR, Mellott MJ, Stranieri MT, Stabilito II, Zhang G, Lynch RJ.
    J Pharmacol Exp Ther; 1995 Jan; 272(1):20-32. PubMed ID: 7815334
    [Abstract] [Full Text] [Related]

  • 22. Effect of rate of administration of recombinant tissue plasminogen activator on efficacy of coronary thrombolysis.
    Prewitt RM, Gu S, Schick U, Ducas J.
    Angiology; 1994 Aug; 45(8):687-94. PubMed ID: 8048778
    [Abstract] [Full Text] [Related]

  • 23. Thrombin inhibition and coronary artery thrombolysis.
    Yao SK, McNatt JM, Anderson HV, Eidt JF, Cui KX, Golino P, Glas-Greenwalt P, Maraganore JM, Buja LM, Willerson JT.
    Trans Assoc Am Physicians; 1990 Aug; 103():1-9. PubMed ID: 2132522
    [No Abstract] [Full Text] [Related]

  • 24. Antiplatelet antibody [7E3 F(ab')2] prevents rethrombosis after recombinant tissue-type plasminogen activator-induced coronary artery thrombolysis in a canine model.
    Mickelson JK, Simpson PJ, Cronin M, Homeister JW, Laywell E, Kitzen J, Lucchesi BR.
    Circulation; 1990 Feb; 81(2):617-27. PubMed ID: 2105175
    [Abstract] [Full Text] [Related]

  • 25. Inhibition of arterial thrombus formation in two canine models: comparison of ancrod, a fibrinogen-depleting agent, the thrombin-inhibitor r-hirudin, and the glycoprotein 11b/IIIa-receptor antagonist Ro 43-8857.
    Rübsamen K, Hornberger W, Kirchengast M.
    Thromb Haemost; 1995 Nov; 74(5):1353-60. PubMed ID: 8607122
    [Abstract] [Full Text] [Related]

  • 26. Selective inhibition of factor Xa is more efficient than factor VIIa-tissue factor complex blockade at facilitating coronary thrombolysis in the canine model.
    Lefkovits J, Malycky JL, Rao JS, Hart CE, Plow EF, Topol EJ, Nicolini FA.
    J Am Coll Cardiol; 1996 Dec; 28(7):1858-65. PubMed ID: 8962577
    [Abstract] [Full Text] [Related]

  • 27. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody.
    Biemond BJ, Levi M, Coronel R, Janse MJ, ten Cate JW, Pannekoek H.
    Circulation; 1995 Feb 15; 91(4):1175-81. PubMed ID: 7850956
    [Abstract] [Full Text] [Related]

  • 28. Simultaneous administration of thromboxane A2- and serotonin S2-receptor antagonists markedly enhances thrombolysis and prevents or delays reocclusion after tissue-type plasminogen activator in a canine model of coronary thrombosis.
    Golino P, Ashton JH, McNatt J, Glas-Greenwalt P, Yao SK, O'Brien RA, Buja LM, Willerson JT.
    Circulation; 1989 Apr 15; 79(4):911-9. PubMed ID: 2494005
    [Abstract] [Full Text] [Related]

  • 29. Coronary thrombolysis. Comparative effects of intracoronary administration of recombinant tissue plasminogen activator and urokinase.
    Gu S, Ducas J, Patton JN, Greenberg D, Prewitt RM.
    Chest; 1992 Jun 15; 101(6):1684-90. PubMed ID: 1600792
    [Abstract] [Full Text] [Related]

  • 30. Influence of heparin and systemic lysis on coronary blood flow after reperfusion induced by the novel recombinant plasminogen activator BM 06.022 in a canine model of coronary thrombosis.
    Martin U, Fischer S, Sponer G.
    J Am Coll Cardiol; 1993 Sep 15; 22(3):914-20. PubMed ID: 8354832
    [Abstract] [Full Text] [Related]

  • 31. Blockade of platelet membrane glycoprotein Ib receptors delays intracoronary thrombogenesis, enhances thrombolysis, and delays coronary artery reocclusion in dogs.
    Yao SK, Ober JC, Garfinkel LI, Hagay Y, Ezov N, Ferguson JJ, Anderson HV, Panet A, Gorecki M, Buja LM.
    Circulation; 1994 Jun 15; 89(6):2822-8. PubMed ID: 8205697
    [Abstract] [Full Text] [Related]

  • 32. Adjunctive selectin blockade successfully reduces infarct size beyond thrombolysis in the electrolytic canine coronary artery model.
    Silver MJ, Sutton JM, Hook S, Lee P, Malycky JL, Phillips ML, Ellis SG, Topol EJ, Nicolini FA.
    Circulation; 1995 Aug 01; 92(3):492-9. PubMed ID: 7543381
    [Abstract] [Full Text] [Related]

  • 33. Prevention of reocclusion following tissue type plasminogen activator-induced thrombolysis by the RGD-containing peptide, echistatin, in a canine model of coronary thrombosis.
    Holahan MA, Mellott MJ, Garsky VM, Shebuski RJ.
    Pharmacology; 1991 Aug 01; 42(6):340-8. PubMed ID: 1946598
    [Abstract] [Full Text] [Related]

  • 34. Arterial diastolic pressure augmentation by intra-aortic balloon counterpulsation enhances the onset of coronary artery reperfusion by thrombolytic therapy.
    Gurbel PA, Anderson RD, MacCord CS, Scott H, Komjathy SF, Poulton J, Stafford JL, Godard J.
    Circulation; 1994 Jan 01; 89(1):361-5. PubMed ID: 8281671
    [Abstract] [Full Text] [Related]

  • 35. Glycoprotein IIb/IIIa receptor antagonist (2S)-2-[(2-Naphthyl-sulfonyl)amino]-3-[[2-([4-(4-piperidinyl)-2-[2-(4-piperidinyl)ethyl] butanoyl]amino)acetyl]amino]propanoic acid dihydrochloride (CRL42796), in combination with aspirin and/or enoxaparin, prevents coronary artery rethrombosis after successful thrombolytic treatment by recombinant tissue plasminogen activator.
    Hong TT, Driscoll EM, White AJ, Sherigill A, Giboulot TA, Lucchesi BR.
    J Pharmacol Exp Ther; 2003 Aug 01; 306(2):616-23. PubMed ID: 12734394
    [Abstract] [Full Text] [Related]

  • 36. Comparison of hirudin and heparin as adjuncts to streptokinase thrombolysis in a canine model of coronary thrombosis.
    Rigel DF, Olson RW, Lappe RW.
    Circ Res; 1993 May 01; 72(5):1091-102. PubMed ID: 8477521
    [Abstract] [Full Text] [Related]

  • 37. Prevention of thrombosis and rethrombosis and enhancement of the thrombolytic actions of recombinant tissue-type plasminogen activator in the canine heart by DMP728, a glycoprotein IIb/IIIa antagonist.
    Lucchessi BR, Rote WE, Driscoll EM, Mu DX.
    Br J Pharmacol; 1994 Dec 01; 113(4):1333-43. PubMed ID: 7889289
    [Abstract] [Full Text] [Related]

  • 38. Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model.
    Wang K, Zhou X, Huang Y, Khalil M, Wiktor D, van Giezen JJ, Penn MS.
    Thromb Haemost; 2010 Sep 01; 104(3):609-17. PubMed ID: 20694285
    [Abstract] [Full Text] [Related]

  • 39. Antagonism of the platelet 5HT2 receptor in the presence of thrombolysis.
    Belcher PR, Drake-Holland AJ, Noble MI.
    Int J Cardiol; 1994 Jan 01; 43(1):11-20. PubMed ID: 8175214
    [Abstract] [Full Text] [Related]

  • 40. Thrombin inhibition and intracoronary thrombus formation: effect of polyethylene glycol-coupled hirudin in the stenosed, locally injured canine coronary artery.
    Rübsamen K, Kirchengast M.
    Coron Artery Dis; 1998 Jan 01; 9(1):35-42. PubMed ID: 9589189
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.